Abstract:Myelodysplastic syndrome (MDS) is a disease affecting clinically and cytogenetically diverse groups of patients. Consequently, MDS patients differ in their response to the individual agents used to treat their disease. Lenalidomide, which has been covered by the national health insurance system of Korea since 2019, is used to relieve transfusion-dependent anemia and has been shown to achieve a genetic response in MDS patients, especially those carrying the del(5q) mutation. Although the mechanism of action of … Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.